Key result
In patients with fulminant myocarditis, veno-arterial extracorporeal membrane oxygenation use was associated with a higher risk of death, durable LVAD, or heart transplant.
Why the study?
Prognoses and long-term cardiac function of patients with fulminant myocarditis have not been fully elucidated across different mechanical circulatory support requirements and histological findings.
Does veno-arterial extracorporeal membrane oxygenation compared to intra-aortic balloon pump or Impella alone worsen the composite of death, durable left ventricular assist device implantation, and heart transplantation in patients with fulminant myocarditis requiring percutaneous mechanical circulatory support?
Observational (n=216)
Yes
Does veno-arterial extracorporeal membrane oxygenation compared to intra-aortic balloon pump or Impella alone worsen the composite of death, durable left ventricular assist device implantation, and heart transplantation in patients with fulminant myocarditis requiring percutaneous mechanical circulatory support?
In patients with fulminant myocarditis requiring mechanical circulatory support, the need for VA-ECMO is associated with a significantly worse prognosis compared to IABP or Impella alone.
Answers are grounded in this paper and cite their sources.
Caution advised interpreting VA-ECMO in fulminant myocarditis; leaves open selection bias versus causal effect.
Background Prognoses and long‐term cardiac function of patients with fulminant myocarditis have not been fully elucidated. Therefore, we clarified the prognoses and long‐term cardiac function according to required percutaneous mechanical circulatory support and histological findings among patients with fulminant myocarditis. Methods and Results We conducted a multicenter retrospective medical record review of 216 patients with fulminant myocarditis requiring percutaneous mechanical circulatory support. Sixty‐one patients were treated with intra‐aortic balloon pump or Impella alone, and 155 patients received veno‐arterial extracorporeal membrane oxygenation and were treated with or without intra‐aortic balloon pump or Impella. Histologically, 107 patients had lymphocytic myocarditis; 34, eosinophilic myocarditis; and 4, giant cell myocarditis. Freedom from composite end point (death, durable left ventricular assist device implantation, and heart transplantation) was 66% at 90 days, 62% at 1 year, and 57% at 6 years. Veno‐arterial extracorporeal membrane oxygenation use was associated with poor prognosis in the multivariable analysis (hazard ratio [HR], 5.27; 95% CI, 1.60–17.36). The eosinophilic myocarditis subgroup showed better prognosis (HR, 0.28; 95% CI, 0.10–0.80) compared with the lymphocytic myocarditis subgroup but not in the multivariable analysis. Ventricular tachycardia/ventricular fibrillation rhythm at admission, high C‐reactive protein level, and no endomyocardial biopsy were also associated with poor prognosis. The left ventricular ejection fraction at 1 year was ≤50% in 16% of patients and was lower in patients with eosinophilic myocarditis (median: 57.9% [48.8–65.0%]) than in those with lymphocytic myocarditis (65.0% [58.6–68.7%]) ( P =0.036). Conclusions Patients with fulminant myocarditis who received veno‐arterial extracorporeal membrane oxygenation had a poor prognosis. Long‐term cardiac function was impaired in some patients, especially those with eosinophilic myocarditis.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an observational in Fulminant myocarditis (n=216). Veno-arterial extracorporeal membrane oxygenation vs. Intra-aortic balloon pump or Impella alone was evaluated on Composite of death, durable left ventricular assist device implantation, and heart transplantation (HR 5.27, 95% CI 1.60-17.36). In patients with fulminant myocarditis, veno-arterial extracorporeal membrane oxygenation use was associated with a higher risk of death, durable LVAD, or heart transplant.
Synapse has enriched 10 related papers. Consider them for comparative context: